Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

20131,420 citationsJournal Articlebronze Open Access

Authors

Tomás Pulido · Chinese Academy of Medical Sciences & Peking Union Medical College

Igor Adzerikho · Chinese Academy of Medical Sciences & Peking Union Medical College

Richard N. Channick · Chinese Academy of Medical Sciences & Peking Union Medical College

Marion Delcroix · Chinese Academy of Medical Sciences & Peking Union Medical College

Nazzareno Galiè · Chinese Academy of Medical Sciences & Peking Union Medical College

Hossein Ardeschir Ghofrani · Chinese Academy of Medical Sciences & Peking Union Medical College

Abstract

Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.).

Topics & Keywords

Pulmonary Hypertension Research and Treatments Cardiovascular Issues in Pregnancy Heart Failure Treatment and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 9, pp. 809-818

DOI: 10.1056/nejmoa1213917

Field-Weighted Citation Impact: 103.58